Orchestra BioMed Appoints Chris Cleary as New Director and Eric Rose ResignsOn January 30, 2025, Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) made notable changes within its Board of Directors. The Board appointed Chris Cleary as a Class II directo

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Health Sciences Acquisitions Co. 2’s 8K filing here.

About Health Sciences Acquisitions Co. 2

(Get Free Report)

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe.

Featured Articles